Scientist, inventor, enterprise professional, and holder of greater than 140 patents will convey ahead PUR Biologics’ regenerative therapeutic patent portfolio to handle unmet wants within the $200 billion osteoarthritis, ache, and cartilage & spinal disc regeneration markets.
IRVINE CA., November 7, 2023 – OrthoSpineNews – HippoFi, Inc. (OTCPK: ORHB) proudly pronounces the appointment of the world’s foremost authority and pioneer of regenerative medication, Gail Naughton, MBA, Ph.D, because the Firm’s “Head of Regenerative Therapeutics and Commercialization.”
Globally acknowledged, Dr. Naughton was awarded the twenty seventh Annual Nationwide Inventor of the 12 months by the Mental Property Homeowners Affiliation in honor of her pioneering work within the subject of tissue engineering and regenerative medication. Dr. Naughton has been a driving power in regenerative medication for over 35 years and holds a confirmed observe document in monetizing vital cell-based therapeutics and bioengineered tissue applied sciences because the founding father of Superior Tissue Sciences and Histogen. Whereas being well-known for taking 4 merchandise from idea, by way of FDA approval, to market launch; and driving two corporations to a publicly traded NASDAQ itemizing, she has broad success in commercializing main manufacturers which proceed to be extensively offered right this moment by establishing partnerships and strategic enterprise alliances with a number of business giants, together with: NYSE Firm Allergan (lately bought by AbbVie for $63B), NYSE firm Smith & Nephew, NYSE firm Medtronic, and Inamed Company (additionally owned by AbbVie).
“I’m delighted and honored to hitch the visionary HippoFi workforce, and to work collectively to remodel healthcare by way of growing and commercializing life-changing regenerative medication options for unmet medical wants,” shared Gail Naughton, MBA, Ph.D – Head of Regenerative Therapeutics and Commercialization.
Dr. Naughton has been a board member on a number of private and non-private firm board of administrators since 1988. She presently is the Chair of the board of the La Jolla Institute, Govt Chair of BioHIP, serves on the boards of NASDAQ firm, Therapeutics MD, and NYSE firm CelSci, and is a member of the Worldwide Enterprise and Fowler Faculty of Enterprise boards at SDSU. Along with serving for 11 years as a board member to the Toronto based mostly, authorities funded, Heart for the Commercialization of Regenerative Medication (CCRM), she has served for a number of years as a member of the bioengineering advisory board of John Hopkins, UCSD, MIT, and Georgia Tech. Dr. Naughton served because the Dean of the Faculty of Enterprise Administration at SDSU from 2002-2011 and obtained her Ph.D. and M.S. from NYU Medical Heart and an MBA from UCLA.
“Dr. Naughton is a globally acknowledged, completed entrepreneur with many confirmed successes, visionary expertise, and unmatched expertise which will probably be very invaluable to HippoFi’s continued progress and success,” mentioned CJ Wiggins, MBA – Founder, Govt Chairman and CEO of HippoFi. “As a pioneering power in our business, including her experience to our completed workforce not solely helps us shortly commercialize and monetize our patented applied sciences, however validates the large market worth of our patent portfolio and solidifies HippoFi as a frontrunner within the regenerative therapeutics market.”
About PUR Biologics
PUR Biologics, a completely owned subsidiary of HippoFi, Inc. (OTCPK: ORHB), is a number one biologic firm dedicated to supporting surgeons and hospitals in offering the very best care for his or her sufferers. PUR Biologics’ full line of biologic merchandise presently embody: superior allografts and demineralized extracellular matrixes (dECM), modern artificial options, mobile derived tissues, and a way forward for subsequent technology regenerative stem cell and progress issue pushed therapeutics for treating osteoarthritis and cartilage regeneration.
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare improvements by way of an in depth gross sales channel community whereas implementing first-to-market options within the multibillion-dollar Biotech, Fintech, and Synthetic Intelligence (AI) markets. HippoFi contains three segments: Regenerative Therapeutics, Digital Funds, and AI, which make the most of the identical buyer channels to commercialize options, drive income, and enhance affected person outcomes.
HippoFi, Inc. is publicly traded beneath the image: ORHB and is headquartered in Irvine, California. For extra info, please go to: www.HippoFi.com and www.PURbiologics.com.